Overview

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Status:
Recruiting
Trial end date:
2024-04-28
Target enrollment:
Participant gender:
Summary
A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Phase:
Phase 2
Details
Lead Sponsor:
Baptist Health South Florida
Collaborator:
Exelixis